TG Therapeutics
TGTX
TGTX
172 hedge funds and large institutions have $454M invested in TG Therapeutics in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 53 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
4% less funds holding
Funds holding: 179 → 172 (-7)
10% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 30
53% less capital invested
Capital invested by funds: $964M → $454M (-$511M)
Holders
172
Holding in Top 10
1
Calls
$27.8M
Puts
$11M
Top Buyers
| 1 | +$19.6M | |
| 2 | +$11.8M | |
| 3 | +$11.4M | |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$8.35M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$7.8M |
Top Sellers
| 1 | -$52.2M | |
| 2 | -$14.4M | |
| 3 | -$11.1M | |
| 4 |
AG
Artal Group
Luxembourg
|
-$7.61M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$5.88M |